Biogen (BIIB) Tops Q1 EPS by 24c; reaffirms guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $210.65 +0.85%
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Total cost and expenses: 1.53B
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.67, $0.24 better than the analyst estimate of $3.43. Revenue for the quarter came in at $2.29 billion versus the consensus estimate of $2.31 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.49.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
